- Home
- ANTA vs ACIU Comparison
ANTA vs ACIU Comparison
Compare ANTA & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTA
- ACIU
- Stock Information
- Founded
- ANTA 2022
- ACIU 2003
- Country
- ANTA Singapore
- ACIU Switzerland
- Employees
- ANTA N/A
- ACIU N/A
- Industry
- ANTA Investment Bankers/Brokers/Service
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- ANTA Finance
- ACIU Health Care
- Exchange
- ANTA Nasdaq
- ACIU Nasdaq
- Market Cap
- ANTA 256.6M
- ACIU 213.3M
- IPO Year
- ANTA 2025
- ACIU 2016
- Fundamental
- Price
- ANTA $12.50
- ACIU $2.04
- Analyst Decision
- ANTA Strong Buy
- ACIU Strong Buy
- Analyst Count
- ANTA 2
- ACIU 1
- Target Price
- ANTA $19.25
- ACIU $12.00
- AVG Volume (30 Days)
- ANTA 34.5K
- ACIU 164.1K
- Earning Date
- ANTA 08-12-2025
- ACIU 08-05-2025
- Dividend Yield
- ANTA N/A
- ACIU N/A
- EPS Growth
- ANTA N/A
- ACIU N/A
- EPS
- ANTA 0.29
- ACIU N/A
- Revenue
- ANTA $51,404,954.00
- ACIU $36,362,036.00
- Revenue This Year
- ANTA $53.90
- ACIU N/A
- Revenue Next Year
- ANTA $40.91
- ACIU $533.21
- P/E Ratio
- ANTA $42.26
- ACIU N/A
- Revenue Growth
- ANTA 320.96
- ACIU 86.71
- 52 Week Low
- ANTA $10.19
- ACIU $1.43
- 52 Week High
- ANTA $27.72
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- ANTA N/A
- ACIU 47.33
- Support Level
- ANTA N/A
- ACIU $2.05
- Resistance Level
- ANTA N/A
- ACIU $2.50
- Average True Range (ATR)
- ANTA 0.00
- ACIU 0.19
- MACD
- ANTA 0.00
- ACIU -0.03
- Stochastic Oscillator
- ANTA 0.00
- ACIU 11.37
About ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.